Revolo Biotherapeutics has entered into a partnership with Northway Biotech, a global end-to-end biopharmaceutical contract development and manufacturing organization (CDMO), to manufacture its binding immuno-regulatory protein, ‘1805.
 
Northway will provide the full scope of its services ranging from cell line development to batch production of ‘1805 active pharmaceutical ingredients (API) and drug product, following current good manufacturing practices (cGMP), with quality assurance and regulatory compliance support.
 
“Northway is the ideal partner for our manufacturing needs,” said Jonathan Rigby, CEO, Revolo Biotherapeutics. “Their expertise in cell fermentation, protein characterization and global outreach will enable our upcoming phase 2 clinical trials for ‘1805. The close collaboration between the two organizations will provide a seamless progression from our current drug supply and future process and formulation advancements.”
 
Vladas Algirdas Bumelis, CEO, Northway Biotech, said, “We are excited to announce our partnership with Revolo Biotherapeutics for the development and manufacturing of ‘1805. Northway Biotech’s global teams in Waltham, MA (U.S.), and Vilnius, Lithuania will closely collaborate with Revolo Biotherapeutics to expedite success in bringing this first-in-class therapy for patients with rheumatoid arthritis and non-infectious uveitis to market quickly and efficiently.”